COMMUNIQUÉS West-GlobeNewswire

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
12/09/2025
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Interim results for the six months ended June 30, 2025
12/09/2025
September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company [...]
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/09/2025
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ( [...]
Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference
12/09/2025
BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s [...]
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
12/09/2025
Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for [...]
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
12/09/2025
ProPhase Labs Stockholders Deliver Strong Mandate at Special Meeting UNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, [...]
Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
12/09/2025
MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently [...]
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
12/09/2025
Ra’anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging [...]
Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
12/09/2025
GAL-101 was well tolerated; excellent safety and pharmacokinetic profile strongly support oral administration GAL-101 effectively crosses the blood-brain barrier, supporting further development in Alzheimer’s disease A [...]
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
12/09/2025
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that [...]
Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
12/09/2025
KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green Med” or the “Company”), a company engaged in diversified industries, today announced that [...]
Update on Information Relating to the General Meeting of September 30, 2025
12/09/2025
Update on Information Relating to the General Meeting of September 30, 2025 61 Founding, Historical, Employee and Executive Shareholders of the Company, Representing Approximately 20.1% of Voting Rights have entered [...]
Mise à jour de l’information relative à l’Assemblée Générale du 30 septembre 2025-Constitution d’un pacte réunissant 61 actionnaires fondateurs, historiques, salariés et dirigeants de la Société portant sur environ 20,1% des droits de vote
12/09/2025
Mise à jour de l’information relative à l’Assemblée Générale du 30 septembre 2025 Constitution d’un pacte réunissant 61 actionnaires fondateurs, historiques, salariés et dirigeants de la Société portant sur environ 20,1 [...]
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
12/09/2025
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/ [...]
Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
11/09/2025
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
11/09/2025
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work ® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List . [...]
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results
11/09/2025
Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs [...]
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
11/09/2025
TORONTO and HAIFA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a pioneering biopharmaceutical company developing exosome- [...]
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/09/2025
NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]

Pages